Oncology Nursing Society (ONS)

The Oncology Nursing Society (ONS) is a professional association that represents 100,000 nurses and is the professional home to more than 35,000 members. ONS is committed to promoting excellence in oncology nursing and the transformation of cancer care. Since 1975, ONS has provided a professional community for oncology nurses, developed evidence-based education programs and treatment information, and advocated for patient care, all in an effort to improve the quality of life and outcomes for patients with cancer and their families.

Standardization of Patient Assessments and Administration Guidelines for Blinatumomab

ONS 2017 – Immunotherapy

Blinatumomab is the only single-agent therapy approved for patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This bispecific antibody induces complete remission, as well as serious adverse events, including central nervous system toxicities and cytokine release syndrome. Oncology nurses play a critical role in early identification and intervention of these toxicities. Read More ›

What Is the Status of Immunotherapeutic Agents Playing a Role in the Treatment of SCLC, and How Should Oncology Nurses Educate and Prepare Patients?

ONS 2017 – Immunotherapy

Small-cell lung cancer (SCLC) is a highly aggressive form of lung cancer associated with high mortality rates. Most patients experience relapse after first-line therapy, and there is no approved drug after second-line therapy. With immune checkpoint therapies rapidly becoming the standard of care in the second-line treatment of metastatic non–small-cell lung cancer, there is tremendous hope that these agents will prove effective in SCLC. Read More ›

Turning on the Light Switch: Development and Implementation of an Immunotherapy Program for a Community-Based Oncology Practice

ONS 2017 – Immunotherapy

Immunotherapy represents a new era in the treatment of cancer patients. Immunomodulating agents increase overall survival and induce highly durable tumor responses in a rapidly expanding patient population. In this dynamic and rapidly evolving landscape, there is significant need to educate nurses and patients on this therapeutic class and its associated toxicities. Read More ›

Identifying and Treating Cytokine Release Syndrome

ONS 2017 – Immunotherapy

Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapeutic approach used in the treatment of various hematologic malignancies. CAR T-cell therapy utilizes gene transfer to reprogram the patient’s own T-cells to recognize and target tumor-associated antigens. Although groundbreaking and incredibly efficacious, CAR T-cell therapy has serious side effects that require prompt identification and intervention. Read More ›

Running the “CAR” Shop: Nursing’s Role in Establishing the Intake and Management Standards of Patients Enrolled in CAR T-Cell Clinical Trials

ONS 2017 – Immunotherapy

Chimeric antigen receptor (CAR) T-cell therapy is considered a living drug. The patient’s own T-cells are genetically engineered to express CARs that recognize tumor-associated antigens. CAR T-cell therapy has proved efficacious in various hematologic malignancies, and is promising in solid tumors. Read More ›

Oncology Nurse Practice: Exemplars in Assuring Safety in Clinical Implementation of Treatment Innovations in Melanoma

ONS 2017 – Immunotherapy

The immunotherapeutic landscape is dynamic and rapidly evolving. Immunomodulating therapies have proved effective in enhancing overall patient survival and inducing highly durable tumor responses. In this exciting and rapidly progressing setting, there is significant need for biosafety procedures to prevent unacceptable exposures. Read More ›

Utilizing Nursing Handoff Communication to Manage Immune-Related Adverse Events in an Outpatient Immunotherapy Clinic

ONS 2017 – Immunotherapy

Immunotherapy represents a groundbreaking advance in the care of cancer patients. It modulates the body’s immune system to promote tumor destruction, and is now considered the fourth pillar of cancer treatment. Immunotherapeutic agents are associated with higher rates of immune-related adverse events that require immediate identification and intervention to prevent treatment cessation or fatal consequences. Read More ›

Leveraging Technology to Optimize the Care of Patients Treated with Immunotherapy

ONS 2017 – Immunotherapy

Immunotherapy represents a revolutionary advance in the care of cancer patients, and is now considered the fourth pillar of cancer treatment. Immunomodulating agents promote tumor destruction and enhance patient survival. They also result in a higher incidence of immune-related adverse events that require prompt recognition for effective management. Read More ›

Combination Therapy in Patients with Metastatic Melanoma, NSCLC, and RCC

ONS 2017 – Immunotherapy

Nivolumab is an immune checkpoint inhibitor proved to extend survival in patients with metastatic melanoma, non–small-cell lung cancer (NSCLC), and renal-cell carcinoma (RCC). When patients receive nivolumab combined with ipilimumab, they experience higher tumor response rates and increased progression-free survival. Patients receiving combined immunotherapeutic agents experience higher rates of immune-related adverse events compared with patients receiving monotherapy. Read More ›

Overcoming HER2/ER Crosstalk: Neratinib Alone or in Combination with Fulvestrant in ER-Positive, HER2-Mutant Metastatic Breast Cancer in the Phase 2 SUMMIT Trial

ONS 2017 – Immunotherapy

The open-label, international, multicenter, multinational, phase 2 SUMMIT trial explored the efficacy and safety of neratinib monotherapy in patients with HER2-mutant metastatic breast cancer (MBC), and neratinib in combination with fulvestrant in patients with estrogen receptor (ER)-positive and HER2-positive MBC. Read More ›

Oncology Nursing Society (ONS)

Page 2 of 3